Abstract
The present study aimed to initially evaluate the anti-tumor effect of orally administered Saphia Alkali K90 in 7,12-dimethylbenz(a)anthracene (DMBA)-induced carcinogenesis in Swiss mice. Mice exposed to DMBA (total dose of 6 mg, p.o.) were treated with SAK90 at 15 ml/kg BW and 45 ml/kg BW daily. The vehicle was given to both normal and diseased controls. The change in body weight, mortality rate, tumor incidence, tumor burden, tumor yield, histopathology, and hematological and biochemical parameters were evaluated after 16 weeks of treatment. 23,26% of DMBA-exposed mice presented neoplasms. SAK90 tended to reduce death, tumor incidence, and tumor yield compared to the DMBA group. The formulation exhibited protective effects against DMBA-induced hepatotoxicity through a trend in drop transaminase levels and increased albumin concentration concurrently compared to the DMBA group. This study suggested that SAK90 has potential anticancer activity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
